EGFR M+ Chemotherapy vs TKI`s
Trial
Compound
RR (%)
Median PFS (mo)
Median OS (mo)
TKI
Chemo TKI
Chemo
TKI
Chemo
IPASS (mut+)
(Mok TS et al, 2009)
Gefitinib
71.2 47.3
9.5
6.3
21.6
21.9
First-SIGNAL (mut+)
(Han JY et al, 2012)
Gefitinib
84.6 37.5
8.4
6.7
30.6
26.5
WJTOG
(Mitsudomi T et al, 2010)
Gefitinib
62.1 32.2
9.2
6.3
30.9
NR
NEJ002
(Inoue A et al, 2009)
Gefitinib
73.7 30.7
10.8
5.4
27.7
26.6
OPTIMAL
(Zhou C et al, 2011)
Erlotinib
83
36
13.7
4.6
22.6
28.8
EURTAC
(Rosell R et al, 2012)
Erlotinib
58
15
9.7
5.2
19.3
19.5
Afatinib (LUX-Lung 3)
(Keating GM, 2014)
Afatinib
56
23
11.1
6.9
28.1
28.2
Afatinib (LUX-Lung 6)
(Keating GM, 2014)
Afatinib
66.9 23
11
5.6
22.1
22.2
